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The Small Molecule Inhibitor DX-52-1 
 
Junru Cui, M.S. 
University of Connecticut, 2011 
Cell migration is a basic biological process that is fundamental to several normal and 
disease processes such as embryonic development, tissue repair, immune function, 
angiogenesis and cancer cell invasion and metastasis. Small organic molecules inhibiting 
cell migration can be used as both research probes and therapeutic agents. DX-52-1, a 
semisynthetic derivative of the natural product quinocarmycin (also known as 
quinocarcin), inhibits the migration of Madin-Darby canine kidney epithelial cells with 
nanomolar concentration. We have identified galectin-3, a multifunctional protein whose 
best-known function is its sugar binding ability, as a secondary target of DX-52-1 with 
functions in cell motility. In addition, we have identified HUK-921, another small 
molecule with antimigratory activity that has far greater selectivity for galectin-3 over 
radixin both in vitro and in cells. Neither of them targets the carbohydrate-binding site of 
galectin-3, moreover,  results indicate that functions of galectin-3 required for cell 
migration are independent of carbohydrate binding ability. We investigated the effects of 
the two inhibitors on cell migration and proliferation in different cancer cell lines and 
discovered that DX-52-1shows promising potency in serveral of the tested ones especially 
triple negative human breast cancer BT20 and MDA-MB-231 cells, suggesting this small 
molecule has a great potential to treat cancers. Six DX-52-1 analogs were synthesized and 
structure-activity relationship (SAR) studies were carried out in cell migration and in vitro 
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competitive binding assays. We provided strong evidence that the mechanism of covalent 
modification of galectin-3 involves elimination of the nitrile group of DX-52-1 followed 
by an attack of a nucleophilic amino acid side chain of galectin-3 on the resulting iminium 
ion. We proposed the similar mechanism for alkylation of radixin by DX-52-1. 
Furthermore, we demonstrated that the hydroxyl group (-OH) of DX-52-1(C-19) plays an 
important role in recognition of DX-52-1 and target proteins.  
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CHAPTER I  
INTRODUCTION TO CHEMICAL GENETICS AND CELL MIGRATION 
 
1.1 Chemical genetics: A brief overview 
Small molecules are useful tools for studying and regulating the functions of biological 
macromolecules such as proteins and nucleic acids. Scientists, using the classical method, 
focus on the effect of small molecules on genes, and then they go from genotype to 
phenotype or oppositely to find the desired information. While classical genetics is 
tremendously powerful, there are certain complementary advantages of the chemical 
genetics. Scientists have been making lots of great achievements by using the classical 
method, however, this approach is labor intensive, unable to correlate the target gene with 
the protein product precisely because proteins usually undergo post-translational 
modification before they fully function; furthermore, it brings consequent problems by 
affecting the abundance of target proteins. For this concern, chemical genetics or chemical 
biology, a new method, has been developing in the past twenty years by which researchers 
can focus on the effects of the small molecules on the proteins of interest directly and be able 
to either enrich our knowledge on life science or benefit the development of new drugs thus 
it attracts more and more attention and grows fast as world spreads. For being more efficient, 
high-throughput methodologies are used to allow for the rapid screening of large collections 
of small molecule compounds with a desired biological activity in chosen biological assays. 
Subsequent mode of action studies then reveal the identification and functions of the targets 
of those hits that are compounds showing activities. Both methods afford the opportunity to 
discover new components of biochemical pathways.  
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Chemical genetics is an approach that utilizes small molecules, coupled with high-
throughput screening methodologies, to discover and regulate the function of biological 
macromolecules, which allows for directly perturbing the protein functions using small 
molecules in a living biological system, rather than indirectly manipulating their genes 
through mutation. The small molecules can be added or washed out at desired times, 
therefore providing much more precise information over when and how the function is 
inhibited. Furthermore, classical genetics is only able to be applicable to a limited number of 
organisms for genetic analysis, while chemical approaches do not have this bottleneck and 
can be applied to any cell type or even the whole-organism where the “drug” delivery is 
accessible. Even though there are several drawbacks for broader application of this method, 
there are also a few recent advances and efforts that have been facilitating to overcome these 
problems (for reviews, see refs. [1-4]). Some of these achievements include: (1) the 
completion of human genome project and the development of protein data bank which 
provide information to identify or verify gene products potentially involved in pathogenesis 
and design small molecules that modulate their function; (2) small molecule libraries with 
great structural and functional diversity generated using combinatorial synthesis largely 
increase the possibility that specific compounds with potential druggability can be screened 
out; and (3) the development in chromatographic and mass spectrometric techniques, 
coupled with other labeling methods, which have remarkably increased the accuracy and 
sensitivity of small-molecule target identification. 
1.1.2 Forward and reverse chemical genetics 
Classical genetics have been traditionally divided into two types, forward and reverse 
approach. Forward genetics, which involves large-scale random mutations of selected 
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genome, followed by screening and identification of the target gene responsible for the 
phenotypic aberration, meanwhile, reverse genetics, which involves mutation of the gene 
of interest first and then characterization of any resulting mutant phenotype. Therefore, 
forward genetic analysis proceeds from phenotype to genotype, whereas reverse genetics 
proceeds oppositely. With direct evolution from classical genetics, chemical genetics can 
be categorized as forward and reverse approaches as well. In spite of the target difference, 
both methods require a collection of small molecules with vast diversity and complex, also 
known as compound libraries, as well as high-throughput screening assays. The sources of 
the compound libraries can be either synthetic compounds or sometimes natural products, 
or combined sometimes. Synthetic organic chemists have been developing methods to 
produce large collections or libraries of “natural product-like” small molecules through 
diversity-oriented synthesis (DOS) [5] to strengthen traditional target-oriented synthesis 
(TOS) [6]. Ideally, DOS leads to effective parallel synthesis of compound libraries in order 
to develop better applications and is an attention-getting area of synthetic chemistry or 
medical chemistry [5, 7, 8].  
Forward chemical genetics involves screening of the libraries of small molecules with a 
desired activity or phenotypic effect on biological processes of a chosen system, usually 
cultured cells but also in organisms such as zebrafish embryo system [9]. The molecular 
targets, proteins in most cases, will be identified following the identification of the 
bioactive small molecules. This method has been leading to the identification of new 
proteins in several biological processes and the generation of compounds for drug 
development (for reviews, see refs. [2, 10, 11]) (Figure 1). What challenges the most in 
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Figure 1.1. General schematic of the chemical genetic process. Forward 
chemical genetics involves screening compound libraries in cells or organism in 
order to identify the hits, small molecules that induce a phenotype change, and 
lead to identification of the molecular targets of the small molecules is in 
succession. Meanwhile, in reverse approach, researchers screen small molecule 
libraries in biochemical assays using known protein targets to identify compounds 
that regulate the function of the protein; the small molecule regulators are then 
applied to investigate the phenotypic effect in a cellular or organismal model.  
 
this method is likely to be the identification of target protein of the hits, bioactive small 
molecule. An affinity-based method followed by a Gel-based MS method are generally 
used to purify and identify the target proteins, in which the bioactive compound can be 
fixed onto a solid support or attached with a tag or label (for instance, biotin, radioisotope 
or fluorophore) without losing the ability binds the protein[12]. In addition, new methods 
such as the nucleic acids microarrays and the yeast two-hybrid system have been being 
developed to facilitate target identification [13-16]. This method is more welcomed used in 
academia to widen our knowledge towards understanding how proteins work in a 
biological system. 
Forward Chemical Genetics
Plate with cells
Add library of small-molecules to
 cells (to animals)
Select small molecules that produce 
the phenotype of interest
N
O
Identify the protein that the
 small-molecule bind to
Reverse Chemical Genetics
Add library of small-molecules to a
purified protein of interest
Plate with cells
Add the molecules that bind to the
protein of interest to cells or animals
Look at the phenotype
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On the other hand, small molecule libraries are screened against known protein of interest, 
kinase most likely, to identify compounds that regulate the function of the target protein 
through binding or disrupting in reverse chemical genetics. As such regulators are 
identified and verified, they can then be tested in living cells or organisms to investigate 
the function of that protein in vivo (Figure 1). This approach, thus, favors the large scale of 
drug discovery efforts in pharmaceutical industries, rather than in an academic lab where a 
relatively small number of validated drug targets are available, a much more collection of 
proteins can be tested without being limited. 
1.2 Cell migration 
Cell migration is a multi-step process that involves dynamic assembly and disassembly of 
cytoskeleton, attachment and detachment to extracellular proteins, and translocation of the 
cell, which plays a fundamental role in many processes that include embryonic 
development, tissue repair, immune function, and angiogenesis. It takes place during the 
whole process of embryonic and tissue development; for instance, the process of 
gastrulation in which a gastrula develops from a blastula by the inward migration of cells, 
in detail, large amount of cells inside the blastocyst change their adhesive properties and 
migrate collectively to form the three germ layers that build up the fundamental body plan 
of the organism [17, 18]. Cell shape change and motility are also crucial to some biological 
processes such as inflammation and immune function [20-25]. Moreover, cell migration 
also plays important role in diseased processes such as cancer cell invasion and metastasis. 
For example, during metastasis, tumor cells move out of the initial location and enter the 
blood stream and then migrate to a new site to spread the tumors (for reviews, see refs. 
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[26,27]). Thus, inhibition of cell migration holds a promise of therapeutic intervention in 
treatment of these diseases.  
1.2.1 Cell sheet migration during epithelial wound closure 
Epithelial cells are bound together to form sheets through several kinds of interactions such 
as tight junctions, adherens, gap junctions and desmosomes that provide an excellent 
model system for studying both cell migration and cell-cell interactions. Cell-sheet wound 
closure assays can be initiated by scratching a wound on a monolayer of cultured cells. 
Cells then respond to the “wounding” by migrating into together to form the monolayer 
again in order to “heal” the wound. In widely used cell-cell adherent cells, such as the 
Madin-Darby canine kidney (MDCK) cells, they move with multiple rows of cells actively 
contributing to cell sheet movement through protrusive cell crawling as a sheet of cells in a 
cohesive and coherent manner without losing cell-cell contacts [28, 29]. Collective 
migration of a continuous cell sheet is a common mode of cell migration during 
development, tissue repair and even in the invasion and metastasis of certain cancers (for a 
review, see ref. [30]). Movement of the cell sheet during wound closure assays in cultured 
epithelial cells has a noticeable similarity to cell sheet movement in vivo during the 
reepithelialization component of wound healing and during embryonic morphogenesis, 
such as in dorsal closure in Drosophila (for reviews, see refs. [31-33]), ventral enclosure in 
Caenorhabditis elegans (for a review, see ref. [34]) and eyelid closure in the mouse foetus 
(for a review see [33]).  
 
1.2.2 Molecular mechanisms controlling cell sheet migration during wound closure 
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Originally, the fundamental cornerstone for understanding cell sheet migration derives 
from investigation on the movement of single cell that crawls individually, not as 
collectives. Abercrombie and colleagues brought up the modern concept of cell migration 
on animal cells [35-40]. They defined the asymmetric morphology of a moving cell, which 
has a broad, flattened sheet of cytoplasm, protrudes at the leading edge of the migrating 
cell is the primary “engine” of motility. Later on, researchers referred it to as a lamella, 
lamellipodium or leading-edge protrusion and the following studies have led to a 
recognition of subcellular domains of different structure and function within this protrusion 
from its very front tip to farther back towards the cell body [41]. The ruffling of the plasma 
membrane is a characteristic feature of many actively migrating cells and related to 
lamellipodia.  They curl up above the plane of the cell and flow backward toward the cell 
body as turnovers; membrane ruffles are presumptive protrusions that allow cells to attach 
and move in three-dimensional environments [35]. 
The cytoskeleton, a network which functions as the “skeleton” or “scaffolding” of the cell 
to control cell shape, contains three polymer systems: actin filaments, intermediate 
filaments and microtubules. It presents in all cells and locates in the cytoplasm, plays 
important roles in both intracellular transport (the movement of vesicles and organelles, for 
example) and cellular division. Dynamic polymerization and depolymerization of actin is 
the driving force for cell motility [42-55]. Microtubles are highly dynamic tubular 
structures and play a crucial role in generation and maintenance of polarity in epithelial 
cells, which are preconditions to lead to cell movement [56, 57]. Apart from that, 
microtubles also play important roles in cell migration through direct and indirect 
connections with actin cytoskeleton [57-62]. Both of them are remarkably important to 
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various other biological processes such as cell division [63]. Whereas intermediate 
filaments, a family of related proteins forming the most heterogeneous filament system, are 
not considered to be an essential active element of cell motility, they interact with cell 
adhesion molecules and other cytoskeletal systems and play critical roles in maintaining 
the mechanical properties of cells and tissues and in the process of signal transduction [64-
66].  
Cell migration is now considered as a dynamic cyclic process [44]. This cycle is triggered 
by responding to external signals to change the polarity of the cells by which cells extend 
protrusions or lamellipodia in the direction of migration by assembling G-actin to F-actin. 
And the system continues to polymerize actin in the direction of movement in order to 
provide driving force. New adhesion sites needed for traction are established at the leading 
edge protrusion, anchoring the protrusion to the substratum. In many cases, actin-myosin 
(actomyosin) filament-based contraction drives the cell body forward, which is led by the 
direction of the protrusion. Detachment of adhesions at the cell rear edge and retraction of 
the trailing edge or “tail” of the cell completes the cycle as a whole process (for reviews, 
see refs. [45, 47-51, 53-55, 67-71]) (Figure 2). The cell moves as cycles repeat. 
Dynamic assembly of F-actin at the front of leading edge of the cell and disassembly of F-
actin and regeneration of and recycling of G-actin behind the lead edge is the driving force 
of crawling animal cells.   Many of other proteins such as alpha-actinin, beta-spectin and so 
on that interact directly or indirectly with actin are also required for initiation and 
persistence of cell migration, and some of these proteins will be described further below. 
The ability of polarized cells to move largely relies on the formation and structure of F-
actin and other proteins associated with the actin network at leading-edge protrusions. The 
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formation of lamellipodial protrusion is tightly correlated with the ongoing actin 
polymerization near the leading-edge plasma membrane. Actin filaments (F-actin), polar 
 
 
 
 
 
 
 
 
Figure 1.2. A migrating animal cell [69].  A migrating cell needs to perform a 
coordinated series of steps to move. It begins with the cell’s response to an 
external signal that leads to the polarization, extension of a leading edge 
protrusion or lamellipodium, formation of new cell adhesions sites which attach 
the leading edge protrusion to the substratum on which the cells is moving, cell 
body contraction, and detachment of adhesions at the cell rear. Nucleation of new 
actin filaments, actin polymerization (formation of filamentous actin or F-actin 
from ATP-bound monomeric actin or G-actin) at the barbed end, filament cross-
linking, network disassembly, dissociation of G-actin (actin depolymerization) at 
the pointed end, cell-substratum adhesion, cell body contraction, and tail 
retraction occur concurrently in different parts of the cell and are controlled by 
other proteins to generate productive, net forward movement. 
 
polymers with variable length, have a fast-growing “barbed” end or plus end (a term based 
on its appearance when myosin head fragments are bound to the filament) and a slow-
growing “pointed” end or minus end. Polymerization is both kinetically and 
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thermodynamically favored at the barbed end over at the pointed end. Actin 
polymerization occurs when G-actin-ATP complex binds to the end of an actin filament 
(Figure 1.3). In the Mg2+-ATP-rich cytoplasm of a cell, F-actin and G-actin are maintained 
in a dynamic steady state, and thus polymerization is a highly controlled process at the 
leading-edge protrusions of the cell [72]. The intracellular concentration of G-actin is 
maintained above the critical concentration (effectively, the Kd) of the barbed end, but 
below that of the pointed end, which ensures one-way growth from the barbed end alone 
under required conditions. The flux of ATP-G-actin association onto available barbed ends 
is balanced by the dissociation of actin monomers from the pointed ends. The process has 
been referred to as treadmilling [72], filament length remaining nearly constant but the 
filament appearing to move forward, that is relative to any attached point outside of the 
cell. Polymerization at the leading edge supplies the force to form protrusion to “push” the 
plasma membrane forward (for reviews, see refs. [68, 69, 73]).  
 
 
 
 
 
 
Figure 1.3. A process of actin polymerization G-actin (globular actin) with 
bound ATP can polymerize, to form F-actin. F-actin hydrolyzes its bound ATP to ADP + 
Pi and release Pi. ADP release from the filament does not occur because the cleft opening 
11 
 
is blocked. ADP/ATP exchange: G-actin can release ADP and bind ATP, which is usually 
present in the cytosol at higher concentration than ADP. 
 
As well as assembly, F-act disassembly is critical for cell motility since it allows recycling 
G-actin from rear portions of the lamellipodia to the front. G-actin bound to Mg2+-ATP has 
a high affinity for the barbed ends of F-actin. After binding the barbed end, actin catalyzes 
the hydrolysis of the γ-phosphate group of the bound ATP. Conversion of ATP-actin to 
ADP-actin causes a conformational change in the actin molecule which results in lowering 
affinity between subunits and monomer dissociation. Since G-actin binds at the barbed end 
in the ATP-bound state, the barbed end is ATP-actin-rich and more stable, while the 
pointed end more ADP-actin-rich and less stable. 
Proteins with F-actin binding and severing activity include gelsolin [153,154], villin [155], 
adseverin [156], actin-depolymerizing factor [157,158] and cofilin [159] that bind to actin 
filaments and modulate their length by breaking them into shorter fragments and 
facilitating dissociation of actin monomers from the pointed end. Cofilin/actin-
depolymerizing factor (ADF) is such protein whose activity is regulated by reversible 
phosphorylation. In detail, cofilin binds aside of actin filaments and leads to dissociation of 
monomers from the pointed end through distortion of the helical twist that facilitates this 
process [49, 74, 75]. The dissociation of ADP-actin from the pointed end regenerates a 
pool of G-actin for additional polymerization. Another major actin filament severing 
protein, gelsolin, functions in a similar way as cofilin except its severing activity relies on 
a critical concentration of Ca2+ (>10−6 M) to take apart actin networks (for reviews, see 
refs. [68, 69, 73]). 
The fact that thymosin β4 (TB4), the main actin-sequestering protein in cells, its ability to 
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bind to G-actin (but not F-actin) can also favor disassembly of F-actin by lowering the 
concentration of free G-actin around the barbed end. Thus, it forms a complex with G-actin 
with a ratio of 1:1 to inhibit spontaneous nucleation [76]. Profilin, unlike TB4, favors 
assembly of F-actin by competing with TB4 for binding to ATP-G-actin in a ratio of 1:1. 
Profilin appears to promote this function in multiple ways [77]. Firstly, profilin promotes 
the exchange of ADP for ATP on G-actin to accelerate the replacement of the pool of 
polymerization-competent ATP-G-actin [78]. Secondly, it acts as a specific carrier of G-
actin and dissociates from G-actin only when the complex has bound the barbed end [78]. 
Therefore, profilin further emphasizes the preference of G-actin for the barbed end. 
Interestingly, profilin has something in common with thymosin β4 in which it also inhibits 
spontaneous nucleation of actin filaments [76, 79, 80]. Thymosin β4 and profilin thus 
ensure that polymerization of actin only occurs when specific nucleating factors or pre-
existing free barbed ends are available. In addition, certain proline-rich proteins, such as 
Ena/VASP, aid in delivering the profilin-ATP-G-actin complex to the sites at barbed ends 
where polymerization occurs and thereby further facilitate actin filaments assembly [81]. 
The correlation of Ena/VASP in the process of forming a filopodium (thin, finger-like 
actin-based projections) has also been demonstrated by analyzing various mutants of 
Ena/VASP and their localization to both the leading edge of protruding lamellipodia as 
well as filopodial tips [82-85]. The formation of F-actin at the barbed end is 
physiologically terminated when capping proteins bind to the end to sterically stop further 
binding of ATP-G-actin (for review, see refs. [68, 69, 73]). 
The mechanisms of actin polymerization can be categorized into three kinds: (1) de novo 
nucleation of new filaments from G-actin, which tends to occur at the plasma membrane; 
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(2) dissociation of capping proteins from filament barbed ends; and (3) severing of 
filaments, which generates a new free barbed end in addition to a pointed end. The de novo 
nucleation that is regulated by multiple actin-nucleating factors including the actin-related 
protein (Arp) 2/3 complex [86], formins [87],  Spir [88], and Cordon-Bleu [89, 90]. The 
first class of de novo actin nucleators to be identified was a seven-polypeptide complex, 
Arp2/3. During initiation of de novo nucleation, Arp 2/3 complex remains attached to the 
pointed end, allowing G-actin to be added to the newly created barbed end. The actin 
filaments that extend from polymerization are orthogonally crosslinked in lamellipodia or 
bundled in filopodia by different actin-binding proteins such as actinin and vinculin to 
yield organelle-excluding F-actin gels with suitable strength to support protrusion [91-94]. 
Actin capping and severing proteins keep the actin filaments short, while Arp2/3 keeps 
initiating new branches that grow to drive the cell moving forward at the leading edge of 
lamellipodial protrusion. When activated by a nucleation promoting factor (NPF), the 
Arp2/3 complex binds to the side of existing filament therefore new filaments are 
nucleated at a ~70
o 
angle from the sides of existing ones in vitro and in vivo; this appears to 
initiate the formation of crosslinked actin networks in lamellipodia. Binding of actin-
crosslinking proteins such as filamin, a Y-shaped dimer that imparts a ~90
o 
angle between 
two crosslinked actin filaments, stabilizes an orthogonal orientation of filaments and 
dramatically stiffens the actin gel [91]. It has been argued that the observed network of 
short, branching actin filaments would be more effective to drive the leading edge forward 
than unbranched filaments, given the flexibility of actin filaments [95-99].  
The nucleation core of the Arp 2/3 complex needs to be activated by one of several NPFs 
such as the WASP family proteins, which include Wiskott-Aldrich Syndrome protein 
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(WASP), neural WASP [100], and the related WASP-family verprolin-homologous 
(WAVE) proteins [101-103], leading to the stimulation of actin polymerization and 
assembly [92, 104]. The C-terminal region of both WASP and WAVE contain a verprolin 
homology domain (V domain) that interacts with actin monomers, while the cofilin 
homology sequence (C domain) associates with the Arp2/3 complex to create a nucleation 
core. One major difference between the two scaffolding proteins is that WASP contains a 
GTPase-binding domain for the small GTPases Cdc42 and Rac which are upstream 
regulators of actin assembly, while WAVE does not. WASP and WAVE normally exist in 
an auto-inhibited conformation with the verprolin homology, cofilin homology, and acidic 
region (VCA) domains of the C terminus folded onto the rest of the peptide sequence, 
preventing  actin and the Arp 2/3 complex from association [103]. 
The formins, another family of actin assembly factors that are single polypeptide of a 
multi-domain complex, nucleate unbranched actin filaments in stress fibers and filopodia 
while the Arp2/3 complex nucleates the branched ones [87,105]. Usually, the FH2 domain 
in the complex is responsible for actin nucleation and remains attached at the barbed end of 
actin filament after nucleation and moves processively as it elongates, keeping away the 
capping proteins [106]. The degree of activity varies largely even though they share a lot of 
similarities on basic properties [105]. 
The Spir protein is another family of actin nucleators that are first identified in Drosophila 
[88, 107]. They are monomeric as formins. Spir proteins are characterized by the presence 
of four WASP homology 2 (WH2) domains that bind actin. Unlike the Arp2/3 complex, 
Spir does not rely on the presence of WASP-related NPFs to be functioned during the 
nucleation of actin filaments. Interestingly, the WH2 domains are also found in the Arp2/3 
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complex but not able to facilitate actin polymerization. Spir binds to the pointed end of 
newly formed actin filaments like the Arp2/3 complex does but it contributes nothing to 
the branched filament networks as the Arp2/3 complex [88, 107]. Recently Cordon-Bleu 
(Cobl) has been characterized as the fourth class of actin assembly protein that nucleates 
actin and may drive morphogenesis of the central nervous system during development as 
well. Cobl is a brain-enriched protein contains three WH2 domains, which are responsible 
for actin binding and nucleation [89]. 
Vast arrays of other proteins show both actin-binding and actin-regulatory abilities also 
exist. For instance, the ERM family proteins including ezrin, radixin, and moesin proteins 
are membrane-associated proteins that bind to actin (for reviews, see refs. [108-110]). 
They function as linkers bridging the membrane and cytoskeleton in actin-rich cell surface 
structures like microvilli, membrane ruffles and other protrusions and are hence considered 
to play essential roles in the regulation of cell morphology and motility. Each of the ERM 
proteins contains three structural domains: the N-terminal FERM domain (named after the 
proteins band 4.1, ezrin, radixin and moesin) that binds to the membrane-associated 
proteins, the α-helical central domain and the C-terminal domain (CTD) that binds to actin 
[111]. ERM proteins exist in a closed inactivated form in which the FERM and CTD bind 
each other in a head-to-tail manner, thereby preventing them from interacting with their 
individual binding partners [112]. Phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) binds 
to the FERM domain and then phosphorylates C-terminal threonine to separate the head-
to-tail form therefore the ERM proteins switch to a open state to be fully functioned. In the 
open state, ERM proteins act as linkers to connect actin filaments to membrane through 
integral membrane proteins such as CD43, CD44, and intracellular cell adhesion molecules 
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(ICAM1-3) or membrane channels and receptors, such as the Na+/H+ exchanger-3 
(NHE3) and various β2-adrenergic receptor (for reviews, see refs. [109, 110, 113, 114]).  
Integrins, transmembrane proteins, are the major actin-linked cell adhesion proteins that 
attach the cell to the extracellular matrix (ECM) via binding to the actin cytoskeleton 
indirectly and facilitate traction during cell migration. The association between the cell and 
the ECM may assist the cell to endure the driving forces of motility without being torn out 
of the ECM. The transient attachments to the matrix during movement are mediated 
primarily by integrin proteins at sites called focal complexes [61], which are generated 
following interaction of integrins with ECM, then their clustering. The clusters likely 
provide sufficient intracellular binding sites to aid in forming the stable signaling 
complexes on the cytoplasmic side of the cell membrane, which are related to the more 
stable focal adhesions at the termini of stress fibers in stationary adherent cells [115, 
116].  Cells attach to a substrate via the interaction of their integrins. When moving, the 
driving forces help the cell relocate to the substrate at its leading edge and concurrently 
release those at its rear edge. When released from the substrate, integrins are transported 
back into the cell by endocytosis; they are then brought through the cell body to its front by 
the endocytic cycle where they are added back to the surface to start a new cycle, 
facilitating the cell to make fresh attachments at its leading front in this manner repeatedly 
(shown in Figure 4, [121]). Integrins are heterodimers containing two subunits alpha and 
beta. They also function as cell surface receptors for a number of extracellular matrix 
proteins, which is critical for cell movement [117]. Their cytosolic domains bind to several 
adaptor proteins, such as talin, vinculin, α-actinin (an actin-bundling protein), and filamin 
A [118-120]. These adaptor proteins are regulated by focal adhesion kinase, integrin-linked 
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kinase, and phosphatidylinositol-3-kinase, which have also been shown to be involved in 
cell migration [116].  
 
 
 
 
 
 
 
 
 
Figure 1.4. A schematic diagram shown for endocytosis and recycling of intergrins in 
cell migration. Cells attach to a substrate via the interaction of their integrins. When 
moving, the driving forces help the cell relocate to the substrate at its leading edge and 
concurrently release those at its rear edge. When released from the substrate, integrins are 
transported back into the cell by endocytosis; they are then brought through the cell body 
to its front by the endocytic cycle where they are added back to the surface to start a new 
cycle, facilitating the cell to make fresh attachments at its leading front in this manner 
repeatedly. 
 
1.2.3 Chemical modulators of cytoskeletal dynamics and cell motility  
There are some small molecules that show regulatory activity in cytoskeletal dynamics and 
cell migration. Among them, some are used as drugs to treat diseases or cancers. For 
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instance, colchicine and colcemide are two natural products that are used to treat some 
diseases by inhibiting tubulin polymerization and disrupt microtubles [122,123]. Both of 
them have also displayed activity in inhibition of cell migration in different cell types and 
systems [124-131]. Moreover, two of these microtuble-targeted drugs, colchicines and 
taxol (which stabilizes the polymerization of tubulin) are used in cancer 
chemotherapy[122,123,132] and the detailed information of these and other inhibitors can 
be found in ref. [69]. 
As to actin, there are three types of direct small-molecule modulators: (1) destabilize actin 
filaments, (2) stabilize actin filaments, and (3) distupt the interaction of actin-binding, and 
actin-regulatory proteins of actin skeleton. Cytochalasin B, cytochalasin D, and latrunculin 
A are some of the cell-permeant destabilizers of actin filaments (for a review, see ref. 
[69]). Cytochalasins function as barbed-end capping proteins, to bind and block the barded 
end of F-actin so that they inhibit the dynamic assembly of F-actin. [133-136]. On the 
contrary, phalloidin, a bioactive component extracted from deadly mushroom Amanita 
phalloides, can stabilize F-actin [137] and has long been conjugated with fluorophore to 
visualize F-actin in fixed cells [138]. However, the poor permeability of phalloidin makes 
its usefulness as a functional cellular probe limited. Luckily, jasplakinolide (jaspamide) has 
been discovered as a F-actin-stabilizing small molecule and highlighted by its great 
permeability [139]. 
Unlike the notable amount of small molecules that directly regulate the functions of actin 
and microtubule, small molecules that interact with actin-binding proteins and other 
regulators of actin function and cell migration are very few. The known ones include 
blebbistatin, regulating the function of class-II skeletal muscle myosins [140]; ML-9, a 
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synthetic compound, inhibiting myosin light chain kinase (MLCK) [141]; Y-27632, 
derivative from synthetic pyridine, is an inhibitor of Rho-associated kinase (Rho-kinase) 
[142]; and wiskostatin, a chemical inhibitor of N-WASP [143]. In addition, we have 
discovered small molecules that target different proteins involved in cell migration and 
identified their targets [144-152].   
This thesis directly addresses the application of a forward chemical genetics approach to 
use DX-52-1, a novel inhibitor of cell migration, as a power tool to define the roles of its 
target protein galectin-3 in the processes of cell migration and cell adhesion; the 
application of SAR study to the study of mechanism of action of this inhibitor with its 
target proteins; and the investigation of its sensitivity and specificity on eleven cancer cell 
lines.  
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CHAPTER II  
SMALL MOLECULE INHIBITORS DX-52-1 AND HUK-921 SHOW DIFFERENT 
SENSITIVITY AND SELECTIVITY IN DIFFERENT CANCER CELL LINES AND 
SAR STUDY REVEALS THE MECHANISM OF ACTION OF DX-52-1 
 
Summary  
Small molecules that inhibit cell migration have potential as both research probes and 
therapeutic agents. Two small molecules DX-52-1 and HUK-921were previously reported 
to show anti-migratory activity in Madin-Darby canine kidney (MDCK) epithelial cells 
with promising potency, yet the mechanism has remained unclear. In this study, DX-52-1 
and HUK-921 were used as probes to investigate their selectivity and sensitivity on eleven 
different cancer cell lines including human breast cancer, human prostate cancer, human 
melanoma and mouse breast cancer cells in the fundamental processes such as cell 
migration and cell proliferation. We discovered that DX-52-1 has promising anti-migratory 
and anti proliferation activity in T47D, MDA-MB-435 and BT-20 cells (nanomolar) and 
MDA-MB-231, 4T1, B16-F10 and B16-BL6 cells (low micromolar) whereas HUK-921 
showed lower potency compared to that of DX-52-1. Further studies suggest that DX-52-1 
has no effect on either the overall expression of radixin and galectin-3 or in the cellular 
localization of galectin-3 in different cell types. However, DX-52-1 treatment has been 
shown to cause a disruption in the organization of actin cytoskeleton in DX-52-1-sensitive 
cells such as T47D and MDA-MB-435, but not in non-sensitive cells such as Du145 siluc 
and 4T07. Six DX-52-1 analogs were synthesized and structure-activity relationship (SAR) 
studies were carried out in cell migration and in vitro competitive binding assays. We 
provide strong evidence that the mechanism of covalent modification of galectin-3 
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involves elimination of the nitrile group of DX-52-1 followed by an attack of a 
nucleophilic amino acid side chain of galectin-3 on the resulting iminium ion. We propose 
the similar mechanism for alkylation of radixin by DX-52-1. Furthermore, we 
demonstrated that the hydroxyl group (-OH) of DX-52-1(C-19) plays an important role in 
recognition of DX-52-1 and target proteins.  
 
 Introduction  
The motility of cells is fundamental biological process that is relevant to finding food or 
mating in simple organisms and crucial processes in embryonic development, tissue repair, 
immune response, inflammation and angiogenesis in mammals [1,2], moreover, cell 
migration also plays important role in cancer cell invasion and metastasis [3,4]. Small 
molecules, that show anti-migratory activity in cancer cells can potentially prevent 
metastasis, hold a great promise for important therapeutic approach. For instance, 
approximate10-20% of breast cancers are found to be triple-negative, negative for estrogen 
receptors (ER), progesterone receptors (PR), and HER2 (HER2), which means that the 
growth of the cancer is not supported by the hormones estrogen and progesterone, nor by 
the presence of too many HER2 receptors. Therefore, triple-negative breast cancer is 
unable to be sufficiently treated by hormonal therapy (such as tamoxifen or aromatase 
inhibitors) or therapies that target HER2 receptors, such as Herceptin. For many 
researchers, there is an intense interest in discovering new drugs that can treat such breast 
cancer [5-10]. Anti-migratory agents such as DX-52-1 have shown the great potential to 
provide remedy for these kinds of problems.  
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We have previously reported that two tetrahydroisoquinoline natural product analogs DX-
52-1 and HUK-921 showed anti-migratory activity in Madin-Darby canine kidney 
epithelial cells with nanomolar and low micromolar concentrations, respectively. Two 
protein targets involved in cell migration, the membrane cytoskeleton linker protein 
radixin and the carbohydrate binding protein galectin-3, were identified as a primary and a 
secondary target of DX-52-1 [11, 12]. We discovered radixin as a primary target of DX-
52-1 by employing a biotinylated derivative of DX-52-1 to pull down and purify target 
proteins from MDCK whole cell lysates followed by a gel-based MS method [12]. DX-52-
1 binds to the C-terminal domain of radixin specifically and covalently,  causing the 
dissociation of radixin, which is a linker protein between the membrane and actin, from 
actin and other certain membrane proteins such as CD44, a cell adhesion protein and a 
receptor for hyaluronic acid [12]. One of the three secondary targets of DX-52-1 we have 
identified is galectin-3 [11]. This protein is a member of a family of carbohydrate-binding 
lectins (for reviews, see refs. [13-15]). Galectin-3 contains a collagen-like domain in N-
terminus that is rich in proline, glycine and tyrosine and a conserved C-terminal 
carbohydrate recognition domain that carries out many important functions in cellular 
processes. Galectin-3 is found in the nucleus and cytoplasm as well as in the extracellular 
matrix where it is involved in cell-extracellular matrix (ECM) adhesion, cell-cell adhesion, 
cell motility, cell differentiation, cell growth, cell proliferation, apoptosis and pre-mRNA 
splicing (for reviews, see refs. [15-21]). Galectin-3 has been implicated in numerous 
normal and disease processes, including inflammation, kidney development, angiogenesis, 
heart failure and cancer progression and metastasis (for reviews, see refs. [17, 18, 22-27]). 
Previously, we provided evidences to prove that galectin-3 is involved in cell migration in 
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MDCK cells and, along with radixin galectin-3 is one of the targets of the anti-migratory 
activity for DX-52-1. However, binding of DX-52-1 to galectin-3 shows little competition 
with binding of β-galactosides, N-acetyllactosamine (LacNAc) or lactose [11]. Hence, we 
considered that DX-52-1 binds outside of the carbohydrate-binding site of galectin-3, 
unlike all the other known inhibitors of galectin-3 (for reviews, see refs. [28, 29]).  
DX-52-1 partially reverses the morphology of galectin-3-overexpressing MDCK cells, 
restoring the cells to more normal epithelial state [11]. DX-52-1 therefore represents a 
potentially useful probe for evaluating the distinct contributions of galectin-3’s non-
carbohydrate-binding functions to cell motility, cell adhesion and cell spreading.  
Hence, two tetrahydroisoquinoline natural product analogs DX-52-1 and HUK-921 that 
have promising anti-migratory activity in MDCK cells were used as powerful probes to 
investigate the effects on different cancer cells in order to improve our understanding of 
cancers and find possible potential drugs for cancer treatment. Therein, we investigated the 
effects of the inhibitors on varied types of cancer cell lines including human breast cancer, 
human prostate cancer, human melanoma and mouse breast cancer cells. We discovered 
that DX-52-1 has promising anti-migratory activity and anti proliferation activity in T47D, 
MDA-MB-435 and BT-20 cells (nanomolar concentration) and MDA-MB-231, 4T1, B16-
F10 and B16-BL6 cells ( low micromolar concentration). HUK-921 showed less potency 
in comparison to DX-52-1. Further studies on the total target proteins expression and the 
localization of the target proteins using immune blotting and immune fluorescence 
microscopy suggest that DX-52-1 has no effect on neither case in cancer cells, meanwhile, 
it has effects on the organization of the actin cytoskeleton in the drug-sensitive cells such 
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as T47D and MDA-MB-435, but not in the non-sensitive cells such as Du145 siluc and 
4T07. 
SAR studies of small molecules allow us to determine which component of the molecule is 
most crucial to its biological activity [30]. In this study, six different analogs of DX-52-1 
were synthesized. Quantitative wound closure assays were carried out in the human breast 
cancer MDA-MB-435 cells along with competitive binding assays with radixin and 
galectin-3 in the presence of biotinylated DX-52-1. Herein, we found that the hydroxyl 
group (OH) has an important impact on DX-52-1 to recognize the target proteins in vitro 
and in vivo. We provide strong evidence that the mechanism of covalent modification of 
galectin-3 involves elimination of the nitrile group of DX-52-1 followed by the attack of a 
nucleophilic amino acid side chain of galectin-3 on the resulting iminium ion. The similar 
mechanism is proposed for alkylation of radixin. 
 
Materials and methods 
Cell culture  
MDA-MB-231, MDA-MB-435, T47D, 4T1, 4T07, MCF7, B16-BL6, B16-F10, and Du145 
siluc cells were cultured in a growth medium containing D-MEM (Dulbecco's Modified 
Eagle Medium) and 10% FBS (Fetal Bovine Serum), BT20 cells were cultured in a growth 
medium of MEM (Minimum Essential Medium) with 10% FBS (Fetal Bovine Serum), 
168FARN cells were cultured in a growth media consisting of D-MEM (Dulbecco's 
Modified Eagle Medium) with 5% FBS (Fetal Bovine Serum) and 5% of NCS (Newborn 
Calf Serum) and grown at 37 °C with 5% CO2 in a humidified tissue culture incubator. 
Early passages of cells cultured from frozen stock cultures were used in all experiments. 
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Main cultures were grown in 75-cm2 tissue culture flasks with medium changed every two 
days. When the cultures reached 90% confluence, the cells were gently washed twice with 
phosphate buffered saline (PBS), and treated with a solution of trypsin/ 
ethylenediaminetetraacetic acid (EDTA) in PBS to detach cells from the flasks. After cells 
were detached, an equal volume of fresh medium was added to inhibit the trypsin activity. 
The cells were resuspended in media and cell density was determined with a 
hemacytometer. Cells were replanted in fresh medium in new tissue culture flasks for 
continued culture and multi-well tissue culture plate for experiments. 
Wound closure assay 
The qualitative wound closure assays were carried out prior to the quantitative ones in 
order to identify those cancer cell lines that have positive response to 
tetrahydroisoquinoline natural product analogs DX-52-1 and HUK-921. In both qualitative 
and quantitative assays, confluent cell monolayers of selected cell lines were treated with 
compounds at various concentrations in cell culture medium. Wounds in the monolayers 
were made using the sterile plastic micropipette tips after incubation at 37°C for 30 
minutes. Pictures were taken every three hours until the control closed by the time of post-
wounding and were then imported into ImageJ for morphometric analyses. Toxicity was 
determined at the end of experiments via the Trypan blue dye exclusion assay.  
Cell proliferation assay 
Cancer cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). The 
media was changed after 24 hrs with media containing varies concentrations of DX-52-1 or 
HUK-921. After another 48hrs, cell numbers were counted with Cell Counting Kit-8 
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(Dojindo), a tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax 
Plus384, Molecular devices) based on manufacturer's protocol. 
Expression and purification of recombinant galectin-3 and radixin 
Glutathione S-transferase (GST) fusion with full length human galectin-3 and mouse 
radixin in the pGEX-2T vector were expressed in BL21 (DE3) Escherichia coli cells. 
Small amount of glycerol stock was picked to seed cultures in 10 mL of Luria-Bertani 
medium with adding 50 µg/ mL ampicillin. After growing the cells overnight at 37°C, the 
culture was transferred to 500 mL autoclaved LB medium then ampicillin was added to a 
final concentration of 50 µg/ mL, followed by incubation until the OD600 was between 0.6 
~ 0.9.  Then, a final concentration of 1 mM IPTG was added and followed by incubation at 
37°C for 4 hours. The cells were then harvested by centrifugation (5,000 rpm for 10 min.). 
The pellets were resuspended in 10 mL ice-cold PBS containing 2 mM EDTA, 0.5% 
Trixton X-100, 100 µg/mL lysozyme, 2 mM DTT (dithiothreitol), 1 µg/mL leupeptin, 1 
µg/mL pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM benzamidine 
on ice for 30 minutes. The homogenized lysates were centrifuged at 15,000 rpm for 
30 minutes at 4°C. The supernatants were collected and then mixed with 500 µL of 
glutathione agarose beads and rotated overnight at 4°C. Beads were washed three times 
with PBS and collected by centrifugation at 5,000 rpm for 10 minutes at 4°C. Thrombin 
(10 units) was added to the solution and incubated overnight at 4°C and protein solution 
was collected and the protein concentration was determined by the UV spectrum. Each 
recombinant protein was ultimately used in a buffer containing 20 mM Tris-HCl (pH 7.4), 
150 mM NaCl, 2 mM EDTA, 2mM DTT, 0.5% (w/v) Triton X-100, 1 µg/mL leupeptin, 1 
µg/mL pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride, and 0.1 mM benzamidine. 
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Competitive DX-52-1 analogs binding assays 
Recombinant full length galectin-3 and radixin were tested under the same conditions. For 
each sample, 20 µM protein (full length galectin-3 or full length radixin) in a buffer 
containing 20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM DTT, 1 µg/mL 
leupeptin, 1 µg/mL pepstatin A, 100 µM PMSF and 100 µM benzamidine with 10 µM 
biotinylated DX-52-1and 50- fold molar excess of free DX-52-1 or DX-52-1analogs. 
Samples were incubated at 4°C for 16 hours, then an equal volume of 2xSDS sample 
buffer was added to each sample, separated by SDS-polyacrylamide gel electrophoresis, 
transferred onto a polyvinylidene difluoride (PVDF) membrane, and blotted with an anti-
biotin antibody ( from Cell Signaling Biotechnology). The samples were detected 
streptavidin-HRP (Sigma) and chemiluminescence (GE health). 
 
Immunoblot Analysis 
Confluent cancer cells grown in 100-mm diameter tissue culture dishes were gently 
washed twice with PBS, and then lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 2 mM ethylene diamine tetraacetic acid (EDTA), 0.5% Trixton-100, 2 mM 
DTT, 1 µg/mL leupeptin, 1 µg/mL pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride 
(PMSF), 0.1 mM benzamidine and 100 µM sodium orthovanadate) on ice for 30 minutes. 
The lysates were separated by centrifugation at 15,000rpm for 30 minutes at 4°C. 
Supernatants were collected and the total protein concentration determined by the Bradford 
assay.  All the lysates were  separated by SDS-polyacrylamide gel electrophoresis, 
transferred onto a polyvinylidene difluoride (PVDF) membrane, and blotted with an anti-
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radixin antibody, anti-galectin-3 antibody and an anti-actin antibody (both from Santa Cruz 
Biotechnology). 
 
Fluorescence Microscopy 
MDCK, T47D, MDA-MB-435 and 4T07 cells were plated onto glass coverslips placed in 
12-well tissue culture plates and grown to confluence. DX-52-1 was added to the plates 
and incubated at 37 °C in 5% CO2 overnight. To visualize galectin-3 localization, cells 
were fixed with 3.7% formaldehyde in PBS for 15 minutes and permeabilized with 0.5% 
Triton X-100 for 15 minutes. The cells were then immunostained with a mouse anti-
galectin-3 monoclonal antibody (Santa Cruz Biotechnology.) and an Alexa Fluor 350-
conjugated goat anti-mouse IgG secondary antibody (Invitrogen/Molecular Probes). 10 µL 
of 10 µg/mL 4'6-diamidino-2-phenylindole (DAPI, Sigma) was placed on each cover slide 
to stain the nuclei of cells.  The cover slides were then mounted to glass slides. T47D, 
MDA-MB-435, 4T07 and Du145 siluc cells were stained for F-actin with 50 nM 
tetramethylrhodamine isothiocyanate (TRITC)-labeled phalloidin (Sigma). The cover 
slides were mounted onto glass slides in Mowiol 4-88 (0.1 g/ml) mounting medium 
(Calbiochem) containing 15 mg/mL antifade agent 1, 4-diazabicyclo [2, 2, 2] octane 
(Sigma). The slides were examined on an inverted fluorescence microscope (Leica DMI 
6000B), and images were captured using a Hamamatsu Orca AG cooled charge-coupled 
device camera.  
 
Nuclei/ cytoplasm ratio of galectin-3 localization 
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Nuclei/ cytoplasm ratio of galectin-3 localization was calculated by the software (Velocity 
software. Inc) 
 
Results 
 
Tetrahydroisoquinoline Natural Product Analogs DX-52-1 and HUK-921 Showed 
Anti-migratory Activity in Different Cancer Cell Lines 
We first investigated the effects of two tetrahydroisoquinoline natural product analogs DX-
52-1 and HUK-921 on the cell sheet migration of eleven different cancer cell lines 
including MDA-MB-231, MDA-MB-435, T47D, 4T07, MCF7, B16-BL6, BT-20, 4T1, 
168FARN, B16-F10, and Du145 siluc. Cell migration was inhibited by both compounds in 
a dose-dependent manner. 
Moreover, minimum inhibitory concentration (MIC), minimum lethal concentration 
(MLC), IC50 for inhibition of cell migration and maximum percent of subtoxic inhibition 
were determined to evaluate the potency and selectivity of the two compounds on the 
cancer cell lines as shown (Tables 1 and 2). DX-52-1 inhibited cell migration on MDA-
MB-231, MDA-MB-435, BT-20, T47D, 4T1, B16-BL6 and B16-F10 cells. HUK-921 
showed anti-migratory activity on MDA-MB-435, BT-20, T47D, B16-F10 and 168 FARN 
cells.  Among all the tested cell lines, the maximum percent of subtoxic inhibition of DX-
52-1 of the drug-sensitive cell lines varied from 67% (MDA-MB-435) to 32% (MDA-MB-
231and 4T1). While for HUK-921, it varied from 49% (T47D) to 28% (MDA-MB-435).   
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Table 1. Effect of DX-52-1 on the Migration of Different Cancer Cell Lines 
 
a
 Minimum inhibitory concentration defined as the lowest concentration at which there was 
a statistically significant decrease in the mean rate of migration in the wound closure assay 
compared to parallel controls from three independent experiments for each compound. 
b
 Half-maximal concentration for inhibition of cell migration, as determined by 
quantitation of the degree of wound closure at the parenthetically indicated times post-
wounding compared to parallel controls for a range of concentrations. 
 c
 Percent inhibition of wound closure at the highest subtoxic concentration (indicated in 
parentheses), measured for the same time post-wounding for each compound as the IC50. 
Cell line 
Minimum 
inhibitory 
concentrationa 
IC50 for 
inhibition of 
cell migration 
(at indicated 
time post-
wounding)b 
95% 
confidence 
interval for 
IC50 
Maximum 
percent of 
subtoxic 
inhibitionc 
Minimum 
lethal 
concentrationd 
MDA-
MB-435 50 nM 
213 nM (24 
h) 
136 nM–
332 nM 
67% (500 
nM) 600 nM 
B16-BL6 3 µM 4.7 µM (12 h) 3.7 µM–5.9 
µM 
66% (10 
µM) 15 µM 
B16-F10 6 µM 7.7 µM (12 h) 4.3 µM–13.8 µM 
42% (12 
µM) 15 µM 
MDA-
MB-231 25 µM 
57.4 µM (24 
h) 
19.7 µM–
167.2 µM 
32% (200 
µM) 500 µM 
BT-20 500 nM 687 nM (24 h) 
500 nM–
944 nM 
37% (25 
µM) 50 µM 
T47D 40 nM 52.3 nM (36 h) 
41.2 nM–
66.4 nM 
50% (100 
nM) 250 nM 
MCF7 No subtoxic 
activity NA
e
 NAe NAe 250 nM 
4T1 1 µM 30.7 µM (12 h) 
9.8 µM–
95.9 µM 
32% (50 
µM) 100 µM 
4T07 No subtoxic 
activity NA
e
 NAe NAe 100 µM 
168FARN No subtoxic 
activity NA
e
 NAe NAe 500 µM 
DU145 No subtoxic 
activity NA
e
 NAe NAe 500 nM 
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The higher the percentage, the more inhibitory the compound is relative to parallel 
controls. 
d
 Minimum lethal concentration defined as the lowest concentration at which there was 
evidence of cytotoxicity based on the trypan blue dye exclusion assay conducted at the 
end of each experiment. 
e
 Not applicable. 
DX-52-1 had a promising drug like dose-dependent inhibitory profile, in which a 
statistically significant minimum inhibitory concentration of 50 nM (unpaired two-tailed 
Student’s t-test for percent wound closure at 24 h for 50 nM DX-52-1 vs. 0.01% dimethyl 
sulfoxide (DMSO) carrier solvent control for data in Table 1.) and a minimum lethal 
concentration of 600 nM on MDA-MB-435, a melanoma cell line, was observed. Also, 
DX-52-1 had an effect on two triple negative breast cancer cell lines BT-20(MIC 500 nM) 
and MDA-MB-231 (MIC 25 µM), a metastatic breast cancer cell line 4T1 (MIC 1 µM) and 
a human ductal breast epithelial tumor cell line T47D (MIC 40 nM). Furthermore, two 
melanoma cell lines B16-BL6 and B16-F10 showed sensitivity to DX-52-1 with the MIC 
value of 3 µM and 6 µM, respectively. HUK-921 showed different effects on migration of 
different cancer cell lines. As seen in Table 2, HUK-921 
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Table 2. Effect of HUK-921 on the Migration of Different Cancer Cell Lines 
a
 Minimum inhibitory concentration defined as the lowest concentration at which there was 
a statistically significant decrease in the mean rate of migration in the wound closure assay 
compared to parallel controls from three independent experiments for each compound. 
b
 Half-maximal concentration for inhibition of cell migration, as determined by 
quantitation of the degree of wound closure at the parenthetically indicated times post-
wounding compared to parallel controls for a range of concentrations. 
 c Percent inhibition of wound closure at the highest subtoxic concentration (indicated in 
parentheses), measured for the same time post-wounding for each compound as the IC50. 
Cell line 
Minimum 
inhibitory 
concentrationa 
IC50 for 
inhibition of 
cell migration 
(at indicated 
time post-
wounding)b 
95% 
confidence 
interval for 
IC50 
Maximum 
percent of 
subtoxic 
inhibitionc 
Minimum 
lethal 
concentrationd 
MDA-
MB-435 10 µM 
24.4 µM (24 
h) 
3.5 × 10-
13–1.7 × 
103 µM 
28% (50 
µM) 100 µM 
B16-BL6 No subtoxic 
activity NA
e
 NAe NAe 5 µM 
B16-F10 500 nM 19.6 µM (24 h) 
12.3 µM–
31.2 µM 
48.7 % (25 
µM) 50 µM 
MDA-
MB-231 
No subtoxic 
activity NA
e
 NAe NAe 50 µM 
BT-20 25 µM NDf NAe NAe 50 µM 
T47D 25 µM 44.5 µM (36 h) 
21.3 µM–
91.3 µM 
49% (50 
µM) 100 µM 
MCF7 No subtoxic 
activity NA
e
 NAe NAe 50 µM 
4T1 No subtoxic 
activity NA
e
 NAe NAe 200 µM 
4T07 No subtoxic 
activity NA
e
 NAe NAe 100 µM 
168FARN 25 µM 43.5 µM (48 h) 
35.7 µM–
52.9 µM 
45% (50 
µM) 100 µM 
DU145 No subtoxic 
activity NA
e
 NAe NAe 25 µM 
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The higher the percentage, the more inhibitory the compound is relative to parallel 
controls. 
d Minimum lethal concentration defined as the lowest concentration at which there was 
evidence of cytotoxicity based on the trypan blue dye exclusion assay conducted at the end 
of each experiment. 
e Not applicable. 
f Not determinable because of extremely narrow concentration-response range. 
has effects on two melanoma cell lines MDA-MB-435 (MIC 10 µM) and B16-F10 (MIC 
500 nM), a human ductal breast epithelial tumor cell line T47D (MIC 25 µM) and a non-
metastic breast cancer cell line 168FARN (MIC 25 µM).  
 
Tetrahydroisoquinoline Natural Product Analogs DX-52-1 and HUK-92-1 Showed 
Anti-proliferation Activity in Different Cancer Cell Lines 
We investigated the effects of DX-52-1 and HUK-921 on the proliferation of the 
aforementioned several cancer cell lines. Cell proliferation was inhibited by both inhibitors 
in a dose-dependent manner. Moreover, minimum inhibitory concentration (MIC), 
minimum lethal concentration (MLC) and IC50 value for inhibition of cell proliferation 
were obtained to evaluate the potency and selectivity of the two inhibitors of the tested cell 
lines as shown (Table 3 and 4). All the tested cell lines showed sensitivity to DX-52-1 
treatment, as seen in Table 3, MDA-MB-231, MDA-MB-435, MCF7, and T47D showed 
the highest sensitivity with a MIC at 100 nM and BT-20 (MIC 1 µM), 4T07 (MIC 1 µM) 
and 168FARN (MIC 1 µM) showed the least sensitivity to DX-52-1 treatment. HUK-921 
also showed anti-proliferation activity in a dose-dependent manner in some cell lines, as 
shown in Table 4. MCF7 (MIC 500 nM) showed the highest sensitivity. 4T1 (MIC 25 
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µM), MDA-MB-435(MIC 25 µM) and 168FARN (MIC 25 µM) showed the least 
sensitivity to HUK-921 treatment. Similar to inhibition of cell migration,  
 
Table 3. Effect of DX-52-1 on the Proliferation of Different Cancer Cell Lines 
a
 Minimum inhibitory concentration, defined as the lowest concentration at which there 
was a statistically significant reduction in mean cell number at 48 h relative to control cells 
at 48 h from three independent experiments in a tetrazolium salt-based assay. 
b
 Half-maximal concentration for inhibition of cell proliferation, calculated from mean cell 
numbers at 48 h for a range of concentrations. 
c
 Minimum lethal concentration, defined as the lowest concentration at which there was a 
statistically significant reduction in mean cell number after 48 h from the mean number at 
Cell line 
Minimum 
inhibitory 
concentrationa 
IC50 for inhibition of cell 
proliferationb 
95% 
confidence 
interval for 
IC50 
Minimum 
lethal 
concentrationc 
MDA-
MB-435 100 nM 163 nM 
142 nM–187 
nM 1 µM 
B16-BL6 500 nM 1.4 µM 1.0 µM–2.0 
µM 5 µM 
B16-F10 500 nM 1.5 µM 1.2 µM–1.8 
µM 5 µM 
MDA-
MB-231 100 nM 179 nM 
71 nM–397 
nM 5 µM 
BT-20 1 µM 1.4 µM 1.2 µM–1.6 
µM 100 µM 
T47D 100 nM 228 nM 213 nM–245 
nM 500 nM 
MCF7 100 nM 176 nM 159 nM–195 
nM 500 nM 
4T1 500 nM 695 nM 535 nM–902 
nM 10 µM 
4T07 1 µM 2.2 µM 1.7 µM–3.0 
µM 10 µM 
168FARN 1 µM 1.96 µM 1.73 µM–2.24 
µM 1 mM 
DU145 250 nM 314 nM 254 nM–387 
nM 500 nM 
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0h (initial cell number). Note: cells are at a lower density in this assay than in the wound 
closure assay. 
inhibition of cell proliferation by DX-52-1 and HUK-921 showed a wide variety of 
sensitivity across the cancer cell lines tested.  
Table 4. Effect of HUK-921 on the Proliferation of Different Cancer Cell Lines 
a
 Minimum inhibitory concentration, defined as the lowest concentration at which there 
was a statistically significant reduction in mean cell number at 48 h relative to control cells 
at 48 h from three independent experiments in a tetrazolium salt-based assay. 
b
 Half-maximal concentration for inhibition of cell proliferation, calculated from mean cell 
numbers at 48 h for a range of concentrations. 
Cell line 
Minimum 
inhibitory 
concentrationa 
IC50 for inhibition of cell 
proliferationb 
95% 
confidence 
interval for 
IC50 
Minimum 
lethal 
concentrationc 
MDA-
MB-435 
No subtoxic 
activity NA
d
 NAd 100 µM 
B16-BL6 1 µM 2.0 µM 1.5–2.7 µM 5 µM 
B16-F10 No subtoxic 
activity NA
d
 NAd 50 µM 
MDA-
MB-231 25 µM 27.3 µM 
13.3 µM–55.6 
µM 50 µM 
BT-20 5 µM 7.1 µM 6.9 µM–7.3 
µM 25 µM 
T47D No subtoxic 
activity NA
d
 NAd 25 µM 
MCF7 500 nM 10.8 µM 9.3 µM–12.7 
µM 50 µM 
4T1 25 µM 35.0 µM 27.3 µM–44.9 
µM 50 µM 
4T07 No subtoxic 
activity NA
d
 NAd 25 µM 
168FARN 25 µM 32.9 µM 31.3 µM–34.6 
µM 100 µM 
DU145 No subtoxic 
activity NA
d
 NAd 25 µM 
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c
 Minimum lethal concentration, defined as the lowest concentration at which there was a 
statistically significant reduction in mean cell number after 48 h from the mean number at 
0 h (initial cell number). Note: cells are at a lower density in this assay than in the wound 
closure assay. 
d
 Not applicable. 
 
Total Protein Expression of Radixin and Galectin-3 in Different Cancer Cell Lines  
Since different cell lines showed different response to the treatment of DX-52-1 or HUK-
921 in cell migration and cell proliferation assays, and with the knowledge that DX-52-1 
targets both radixin and galectin-3 whereas HUK-921 targets galectin-3, we investigated 
the total expression level of both target proteins in all tested cancer cell lines in order to 
correlate the anti-migratory activity of the two small molecule inhibitors on different cell 
lines with either galectin-3 or radixin. As shown in Table 5, radixin is expressed in all cell 
lines except 168FARN but galectin-3 is expressed in T47D, MCF7, MDA-MB-435, MDA-
MB-231 and BT20 cells. 
 
MD
CK 
T47D MCF
7 
4T07 168 
FARN 
MDA-
MB-435 
BT 
20 
B16-
BL6 
MDA-
MB-
231 
4T1 B16-
F10 
Du 
145 
siluc 
Rad + + + + _ + + + + + + + 
Gal-3 + + + _ _ + + _ + _ _ _ 
DX + + _ _ _ + + + + + + _ 
HUK + + _ _ + + _ _ _ _ + _ 
 
Table 5. The Expression of Radixin or Galectin-3 in Different Cell Lines 
All cell cultures were incubated at 37°C in 5% CO2 until more than 90% confluent. Cells were 
lysed after washed twice by PBS and the total protein concentration was measured by Bradford 
assays and then subjected to SDS-PAGE with the same amount. Galectin-3 or radixin was probed 
by antibody in each case. Results were obtained by the means of more than three individual 
experiments.  
 Among all the cell lines that express both radixin and galectin
cells were sensitive to both of the inhibitors.
 
Tetrahydroisoquinoline Natural Product 
Degradation of Galectin-3 or Radixin in C
We investigated the effect of DX
galectin-3, a primary and secondary target protein of DX
The results of the immunoblot analysis (Figure 1) suggested that 
in degradation of galectin-3 or 
 
 
    A  
        
        B 
  
         C 
 
Figure 1. DX-52-1 Does Not Result in Degradation of Galectin
 
DX-52-1 does not result in degradation of galectin
MDCK and T47D cell cultures were incubated at 37°C in 5% CO
confluent. Cells were lysed after treatment with 500nM DX
whole-cell extracts were subjected to SDS
absence or presence DX
were obtained by the means of more than three individual experiments. (A) Galectin
was probed from T47D whole cell lysate in the absence or presence of DX
Galectin-3 was probed from MDCK whole cell lysate in the absence or pre
52-1; (C) Radixin was probed from T47D (left) and MDCK (right) whole cell lysate in 
the absence or presence of DX
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-3, MDCK, T47D, MDA
 
Analog DX-52-1 Does Not Result in 
ells  
-52-1 on the overall expression level of radixin and 
-52-1, in MDCK and T47D cells. 
DX-52-
radixin in cells. 
 
-3 or Radixin 
-3 or radixin in MDCK or T47D cells. 
2 until more than 90% 
-52-1 for 12 hours, and 
-PAGE. Intensity of bands from samples in the 
-52-1 was calculated and analyzed by Image J software. Results 
-52-1. 
-MB-435 
1 does not result 
in Cells 
-3 
-52-1; (B) 
sence of DX-
  
DX-52-1 Does Not Affect 
Organization of the Actin C
It is known that the cytoplasmic 
associated with cancer cell invasion and metastasis [31
1 does not result in degradation of galectin
understand how DX-52-1 interacts with galectin
cancer cell lines> We investigated the localization of galectin
actin cytoskeleton in different 
the consideration of variety of samples, both drug
2A), T47D (Fig. 2B) and MDA
(Fig. 2D) were investigated for the localization of galectin
cytoplasm. Based on the nuclei/ cytoplasm ratio of galectin
significant difference on localization of galectin
whether or not they are drug
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52 
the Localization of Galectin-3 in Cells but Disrupts the 
ytoskeleton in Drug-sensitive Cancer Cells
versus nuclear expression of galectin
-36]. Based on the fact 
-3 in cells, more information is needed to 
-3 in cells and inhibits the cell migration in 
-3 and the organization of the 
types of cells in the absence or presence of DX
-sensitive cell lines such as MDCK (Fig. 
-MB-435(Fig. 2C) and non-sensitive cell line such as 4T07 
-3 in both nucleus and 
-3, we found that there is no 
-3 in all four cell lines regardless of 
-sensitive (Fig. 2E). 
 
-3 in vivo is 
that DX-52-
-52-1. With 
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Figure 2. The Treatment of DX
(A), (B), (C) and (D) are images showing MDCK, T47D, MDA
DAPI for nucleus and probed by a secondary fluorescence labeled antibody to detect a primary 
anti-galectin-3 antibody. Confluent monolayers of cells were washed twice
treated with carrier solvent DMSO as controls or DX
T47D, 500 nM for MDA-MB
imaging, as described in Experimental Procedures. 
ratio of galectin-3 expressed in MDCK, T47D, MDA
presence of DX-52-1. The ratio was calculated using the software (Velocity software. Inc.).
 
DX-52-1 Treatment Causes a Disruption in
Cytoskeleton in Drug-sensitive Cell B
More information is needed to fully explain the facts that DX
migratory activity in different cancer cell lines. By binding to eith
DX-52-1 has direct or indirect interaction with the actin network and inhibits cell 
migration through the network. Therefore, we investigated the effect of DX
organization of the actin cytoskeleton in drug
54 
-52-1 Does Not Affect the Localization of Galectin
-MB-435 and 4T07 cells stained by 
 by PBS buffer and then 
-52-1 of 500 nM for MDCK, 200 nM for 
-435 and 50 µM for 4T07, 12 h later, fixed and processed for 
Scale bar = 50 µm. (E) The nuclei/cytoplasm 
-MB-435 and 4T07 cells in the absence or 
 the Organization of the Actin 
ut Not in Non-sensitive Cells  
-52-1 shows different anti
er radixin or galectin
-sensitive cell lines, T47D and MDA
-3 
 
-
-3, 
-52-1 in the 
-MB-
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435, and non-sensitive cell lines, 4T07 and Du 145 siluc, in the absence or presence of 
DX-52-1 using immune fluorescence  
 
 
 
 
               A  
 
 
 
                       
                        
 
 
 
                      B 
 
 
 
 
 
Figure 3. DX-52-1 Treatment Causes a Disruption in the Organization of the 
Actin Cytoskeleton in Drug-sensitive Cell Lines Such as T47D and MDA-MB-435 
But Not the Non sensitive Cells Such as Du145 siluc and 4T07 
(A)  (B) are images showing T47D, MDA-MB-435, Du145 siluc and 4T07 cells stained for F-
actin with 50 nM tetramethylrhodamine isothiocyanate (TRITC)-labeled phalloidin (Sigma). 
Confluent monolayers of cells were washed twice by PBS buffer and then treated with carrier 
solvent DMSO as controls or DX-52-1 of 200 nM for T47D, 500 nM for MDA-MB-435, 50 
µM for 4T07 and 400 nM for Du145 siluc, 12 h later, fixed and processed for imaging, as 
described in Experimental Procedures. Scale bar = 50 µm.  
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microscope. We found that DX-52-1 treatment causes a disruption in the organization of 
the actin cytoskeleton in drug-sensitive cell lines, such as T47D and MDA-MB-435 (Fig. 
3A ), but not in non-sensitive cell lines, such as 4T07 and Du 145 siluc (Fig. 3B).  As seen 
in the images (Fig. 3A top), the filopodia of MDA-MB-435 cells are very long and the 
cells spread more without the inhibitor treatment, whereas the cells with compound 
treatment are rounder and have very short filopodia. The lamellae in T47D cells also 
showed difference in the absence or presence of DX-52-1 (Fig. 3A bottom). As seen in the 
figure, the actin network in the untreated cells is well organized, fine and smooth, 
thoroughly distributed across the cells while the network is not evenly spread in the treated 
cells. This observation implies that the network is partially broken at the edge of cells and 
more concentrated in the cytoplasm by the treating the compounds.  Furthermore, as shown 
in Fig. 3B, there is no difference for the actin cytoskeleton in DX-52-1 non-sensitive 4T07 
and Du145 siluc cells with or without compound treatment, which is unlike in drug-
sensitive cell lines T47D and MDA-MB-435. 
 
 SAR Studies of DX-52-1 Suggests that Hydroxyl Group (OH at C19) is Crucial for 
Target Identification 
Six analogs of DX-52-1 were synthesized (shown in Fig. 4) and the structures were 
confirmed by nuclear magnetic resonance (NMR) and mass spectrometry (MS).  These 
compounds were used in wound closure assays and competitive binding assays. Herein we 
discovered that among these compounds DX-A-4 showed similar competitive binding 
ability on both target proteins galectin-3 and radixin and similar anti-migratory activity on 
MDA-MB-435 cancer cells. The rest of the analogs showed a partial or total loss of the 
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ability to compete with biotinylated DX-52-1 binding to the two target proteins. 
Furthermore, a loss of anti-migratory activity on MDA-MB-435 cancer cells was also 
observed (Table 6.). Thus, we believe that the nitrile group is responsible for the inhibitors 
binding to the target proteins in vivo and in vitro and the hydroxyl group plays an 
important role in recognition by target proteins can be supported. 
       
 
Discussion  
The identification of radixin and galectin-3 as the target proteins of DX-52-1 in the process 
of cell migration gives an opportunity to define the roles of these two proteins in cell 
motility and other important biological processes, which also holds the promise of a 
potential cancer therapy. Furthermore, the compound HUK-921, which shares structural 
similarity with DX-52-1 also showed anti-migratory activity in MDCK cells. The fact that 
DX-52-1 and HUK-921 inhibit cell migration [11] and bind to galectin-3 outside of its 
carbohydrate-binding site of galectin-3 indicates that these compounds also inhibit other 
galectin-3 functions that may also be important in cell migration. Furthermore, since 
LacNAc does not inhibit migration of MDCK cells, the function(s) of galectin-3 involved 
in cell motility in this system appear independent of its  β-galactoside-binding activity. In 
addition, while less potent than DX-52-1, the remarkable selectivity of HUK-921 for 
galectin-3 over radixin suggests that target selectivity derives from specific recognition 
interactions between protein and small molecule prior to alkylation. Therefore further 
development of structurally related molecules would yield compounds with yet different 
selectivities, such as those with greater selectivity for radixin over galectin-3. Because of 
galectin-3’s multiple roles in cancer pathogenesis, proliferation, and spreading of 
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Table 6. Structure-activity Relationship Study of DX-52-1 and Its Analogs 
 
 
 
 
 
 
 
 
Compound            R1          R2          R3        R4         R5          IC50/Activity              Binding ability 
    
   DX-52-1           -CN        -OH      -OCH3     -H     -COOH          213 nM              Rad, 100%; Gal-3,100% 
    
 
   DX-A-1             -H          -OH      -OCH3     -H     -COOH            NA                      Rad, 22.22±12.66%;  
                                                                                                                                 Gal-3, 3.76±4.08 
   
   DX-A-2  -C≡C-H/TMS  -OH       -OCH3     -H     -COOH            NA                      Rad, 16.51±6.36% 
                                                                                                                                  Gal-3, 4.51±1.31% 
 
   DX-A-3             -H          -OH      -OCH3     -H     -CH2OH            NA                      Rad, 22.84±14.56% 
                                                                                                                                   Gal-3, 3.51±1.10% 
 
   DX-A-4           -CN        -OH      -OCH3     -Br     -COOH          218 nM                  Rad, 133.1±81% 
                                                                                                                                       Gal-3, 72.6±48.9% 
 
   DX-A-5            -CN     -OOCCH3  -OCH3     -H     -COOH            NA                      Rad, 52.5±1.15% 
                                                                                                                                   Gal-3, 47.7±28.6% 
 
   DX-A-6           -CN     -OOCCH3  -OCH3     -Br    -COOH            NA                      Rad, 25.6±8.16% 
                                                                                                                                   Gal-3, 35.7±1.88% 
 
Note: Normalized Relative Competition Equation 
 
 
 
 
Unlike a percentage simply based on DX-52-1 Band/Analog Band ratio, the above 
formula returns a value of 0% if the analog band is equal to control band (no competition) 
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and 100% if analog band is equal to DX-52-1 band (competition unaffected). All IC50 
values were calculated for inhibition of wound closure at the indicated times post-
wounding with normalization to parallel controls by using five different subtoxic 
concentrations in concentration-response experiments. Each concentration for MDA-MB-
435 cancer cells assay involved at least three separate experiments and was considered a 
bioactive concentration if there was statistically significant inhibition with ρ < 0.05 by an 
unpaired two-tailed Student’s t test. 
metastasis, there is considerable interest in the development of new galectin-3 inhibitors. 
Existing galectin-3 inhibitors are carbohydrate or peptide-based which target the 
carbohydrate-binding site of the protein’s C-terminal carbohydrate-recognition domain (for 
reviews, see Refs. [28,29]). DX-52-1 and HUK-921 are thus unique in that they 
specifically bind galectin-3 outside of its carbohydrate-binding site. Thus, it is worth 
investigating when they are used as powerful probes to study the effects on different cancer 
cells in the processes of cell migration and cell proliferation.   
It is very interesting that DX-52-1 and HUK-921 showed different anti-migratory activity 
and anti-proliferation ability on the eleven different cancer cell lines that cover a large 
range of cancer types. This finding indicates that the two small molecule inhibitors are 
more specific to certain type of cancers than others. Furthermore, the selectivity of a 
compound is crucial to higher efficacy and lower side effects. Results shown in Table 1-4 
exhibit that DX-52-1 has a promising drug like dose-dependent inhibitory profile on 
MDA-MB-231, MDA-MB-435, BT-20, T47D, 4T1, B16-BL6, B16-F10 cells,  which also 
could be true for HUK-921 in terms of anti-migratory activity on MDA-MB-435, BT-20, 
T47D, B16-F10 and 168 FARN cells. Although HUK-921 showed far greater selectivity 
on galectin-3 over radixin, HUK-921 acted largely differently on tested cancer cells in the 
process of cell migration. Therefore we tried to answer the question that do these two 
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inhibitors act differently in terms of cell migration and cell proliferation because of the 
different selectivity they showed on the two target proteins radixin and galectin-3?  If so, 
can we correlate the selectivity of the inhibitors with the expression level of the two target 
proteins? In order to uncover the information behind, we investigated the overall cellular 
expression of the two proteins on all the tested cell lines and tried to find the correlation 
between them. As seen in Table 5, radixin is expressed in all tested cell lines except 
168FARN and galectin-3 is expressed in T47D, MCF7, MDA-MB-435, MDA-MB-231 
and BT20 cells. Both of the compounds, DX-52-1 and HUK-921, showed inhibition on 
MDCK, T47D, MDA-MB-345 and B16-F10 cells. Unfortunately, the relation between the 
selectivity of the two inhibitors and the protein expression level is more miscellaneous than 
being straightforward or simply connected, which implies that the living cell is a much 
more complicated system rather than being a model to do biological assays with. For 
instance, both DX-52-1 and HUK-921 showed anti-migratory activity on MDCK, T47D, 
MDA-MB-345 and B16-F10 cells in which both radixin and galectin-3 are expressed in the 
first three cell lines but not in B16-F10 cells. Surprisingly, neither DX-52-1 nor HUK-921 
showed inhibition on MCF7 cells even though both target proteins are expressed in this 
cell line. HUK-921 inhibits cell migration in 168FARN cells which indicates that the 
compound targets some other protein(s) besides galectin-3 involved in cell motility since 
neither radixin or galectin-3 is expressed in 168FARN cells.  In addition, HUK-921 also 
shows anti-migratory activity in B16-F10 cells in which galectin-3 expression is not 
detected by immune blotting assays. Since, it is hard to derive a direct correlation from the 
information obtained based on the overall cellular expression of the two target proteins and 
the selectivity of the two inhibitors, further studies are needed to aid in better 
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understanding on how the small molecule inhibitors work in cells and how we can develop 
a better inhibitor with higher selectivity and potency.  Based on the results we obtained 
from investigating eleven cancer cell lines, it is most likely that HUK-921 targets other 
proteins involved in cell motility besides galectin-3 in living cells. In addition the “big” 
size of HUK-921 in consideration of Lipinski's Rule of Five makes it a less potential drug 
to be pursued in further studies  
Previously we learned that the sensitivity of MDCK cells to DX-52-1’s anti-migratory 
activity is reduced when either radixin [12] or galectin-3 is overexpressed [11]. This is 
most likely due to the fact that both of the proteins are specific DX-52-1 binding proteins; 
overexpression of either protein effectively “titrates” out a large proportion of the soluble 
DX-52-1, reducing its concentration in cells and thus its ability to inhibit either protein 
completely. Binding of small molecule inhibitors to the target proteins often causes 
conformational changes of the complexes, which leads to degradation of the proteins as the 
cutting sites of the proteins may be “exposed” to the proteases. Does such thing happen 
during binding of DX-52-1 to radixin or galectin-3 in the living cells? That is a very 
interesting question to be asked here because changes were observed when DX-52-1 was 
used to treat cells in the process of cell migration. Therefore further investigation will be 
very helpful for understanding how DX-52-1 works with radixin or galectin-3 in living 
cells. 
Unlike radixin, galectin-3 is ubiquitously expressed in cells and can be found in the 
cytoplasm, nucleus and extracellular matrix [37, 38]. The dynamics of galectin-3’s roles in 
the cytoplasm and nucleus have yet to be determined. For instance, galectin-3 undergoes 
post-translational modification, phosphorylation of a serine residue by the protein kinase 
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casein kinase 1 (CK1), which triggers the signals to export galtecin-3 to the cytoplasm thus 
can function as a molecular switch to activate the carbohydrate binding ability [39-42]. In 
addition, the nuclear localization of galectin-3 is perhaps relevant to cell proliferation 
because it plays an essential role in the process of splicing pre-mRNA [43]. In cancer cells, 
galectin-3 also plays a significant role in tumor progression [44–49]. In some cancers, 
galectin-3 shows up-regulation on growth by inducing cyclin D1 and c-Myc in the nucleus 
of human breast cancer [44-46]. Moreover, the cytoplasmic/nuclear expression ratio of 
galectin-3 is associated with tumor invasion and metastasis in vivo [31-36]. In many cases, 
the level of nuclear galectin-3 expression is reported largely different in cancer cells [31-
33] compared to normal cells and can be used as a predictive factor and a crucial 
pathological parameter [34-36]. 
The data presented here (Fig.1) show that DX-52-1 does not result in degradation of 
galectin-3 or radixin in either MDCK or T47D cells although both of the cell lines are very 
sensitive to DX-52-1 treatment (low nanomolar concentration). Thus, DX-52-1’s inhibition 
of cell migration is not due to the degradation of the target proteins. The change of the 
localization of the target proteins may contribute to the inhibition of cell migration by the 
treatment of DX-52-1. Herein, we investigated whether or not DX-52-1 affects the 
localization of galectin-3. In comparing the images from immune fluorescence microscopy, 
no clear change was observed on localization of galectin-3 in MDCK, T47D, 4T07 and 
MDA-MB-435 cells in the absence or presence of DX-52-1 (Fig.2 A,B,C,D). Quantitative 
calculations were carried out by comparing the amount of galectin-3 localized in the 
nucleus and cytoplasm, which also exhibited no significant difference in nuclear to 
cytoplasmic ratio of the protein. (Fig.2 E). All the data showed here indicates that DX-52-1 
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treatment does not alter the localization of galectin-3 in various cell lines in spite of their 
sensitivity to the compound. These observations may explanation that DX-52-1 does not 
disrupt the interaction between galectin-3 and importin, another protein responsible for 
nuclear translocation of galectin-3. Further studies such as the identification of the binding 
site of galectin-3 to DX-52-1 will enhance our knowledge on the mechanism of action of 
DX-52-1 on its target proteins.  
Interestingly, when we examined the organization of actin cytoskeleton on different types 
of cell lines including DX-52-1 sensitive and DX-52-1 non-sensitive ones in the absence or 
presence of the compound, we found that DX-52-1 disrupted the organization of actin 
cytoskeleton on T47D and MDA-MB-435 cells but not 4T07 and Du145 siluc cells. DX-
52-1 inhibits cell migration by targeting radixin and galectin-3. Radixin, along with ezrin 
and moesin, is a non-enzymatic membrane-cytoskeleton linker whose functions have been 
implicated in a range of processes, particularly at actin-rich cell-surface structures (for 
reviews, see refs. [51-55]). DX-52-1 acts not by inhibiting an enzymatic activity but by 
disrupting protein-protein interactions. Yet it may not be the reason here because radixin is 
expressed in all of the cell lines being tested. We just found that galectin-3 binds to alpha-
actinin (unpublished data), an actin binding protein, that plays key role in the organization 
of actin cytoskeleton, DX-52-1 disrupts the interaction between them. This gives very 
strong evidence to explain why DX-52-1 shows effects in T47D and MDA-MB-435 cells 
in which galectin-3 is expressed but not in 4T07 and Du145 siluc cells in which galectin-3 
is not detected.  
Previously, we proposed that the mechanism of covalent modification of galectin-3 may 
involve elimination of the nitrile group of DX-52-1 or HUK-921 followed by the attack of 
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a nucleophilic amino acid side chain of galectin-3 on the resulting iminium ion. The 
similar mechanism has been proposed also for alkylation of radixin by DX-52-1 [12]. But 
the evidence has not been revealed yet. We further investigated the structure-activity 
relationship study which can provide much information in understanding the correlation of 
the chemical structure and biological activity [56]; moreover, it can facilitate learning the 
mechanism of action.  
The series of experiments presented here show that the replacement of nitrile group with -
H or -C≡CH (TMS) on DX-52-1 led to a total loss of its binding ability to the target 
proteins (radixin and galectin-3) in vitro and anti-migratory activity to a DX-52-1 sensitive 
cell line MDA-MB-435 in vivo. In addition, analogs that are acetylated on the hydroxyl 
group significantly reduced the binding ability of the compounds to their target proteins 
with no subtoxic activity in cell migration. On the other hand, bromination on the phenyl 
ring of the compounds had no effect on either the binding ability in vitro or the anti-
migratory activity in vivo.  
Taken together, these three lines of evidence strongly suggest that the nitrile group is 
responsible for the compound’s binding to the target proteins as proposed previously [12]. 
First, DX-52-1 and its analogs were investigated in competitive binding assays with 
radixin and galectin-3. The fact that the analogs with their nitrile group being replaced with 
-H or -C≡CH (TMS) lost the ability to bind the two proteins and also lost their anti-
migratory ability indicates that nitrile group plays important role for the reactivity of the 
inhibitor both in vitro and in vivo. This does not necessarily rule out the possibility that 
there might be other functional groups contributin to the reactivity as well. Apart from that, 
we also found that acetylation on the hydroxyl group caused a statistically significant 
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reduction of the reactivity of the analogs in binding assays and anti-migratory activity, 
which suggests that the hydroxyl group may contributesin recognition of the target 
proteins. Bromination on the phenyl ring, on the other hand, showed no effect in either set 
of experiments. Herein, we provide strong evidence that the mechanism of covalent 
modification of galectin-3 involves elimination of the nitrile group of DX-52-1 followed 
by the attack of a nucleophilic amino acid side chain of galectin-3 on the resulting iminium 
ion. The similar mechanism is proposed for alkylation of radixin (Scheme 1). 
 
 
 
                                                        CN- 
 
 
 
Scheme 1. Proposed mechanism of action of DX-52-1 on target proteins 
 
In the future study, a structure-based template can be used to develop inhibitors with 
higher sensitivity and greater selectivity towards potential drugs to treat cancers.  
 
Significance 
We show that two small molecule inhibitors DX-52-1 and HUK-921 have effects on the 
eleven different cancer cell lines in the process of cell migration and cell proliferation. 
Among these cell lines, DX-52-1 shows very promising potency on triple-negative human 
breast cancer BT-20 and human breast cancer MDA-MB-435 and T47D cells. In addition it 
also shows great selectivity over various cancer cell lines. DX-52-1 disrupts the 
organization of the actin cytoskeleton of drug-sensitive cell lines but have no effect on 
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non-sensitive ones. Six analogs of DX-52-1 were synthesized and employed in a SAR 
study from which we provide strong evidence that the mechanism of covalent modification 
of galectin-3 involves elimination of the nitrile group of DX-52-1 followed by the attack of 
a nucleophilic amino acid side chain of galectin-3 on the resulting iminium ion. We 
propose the similar mechanism for alkylation of radixin. We also found that the hydroxyl 
group (-OH) on DX-52-1 (C19) plays a very important role in the recognition of the the 
target proteins.  
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1. Time course of wound closure in 4T1 cell monolayers of DX-52-1. Percent 
wound closure is depicted as a function of time after treatment with: 0.05% DMSO or 
various concentrations of DX-52-1. Each concentration involved at least three separate 
experiments each with multiple replicates (n, number of separately treated wounds with 
one wound per well on multiwell plates). Percent closure values are means ± standard error 
of the mean (SEM). Each concentration was considered a bioactive concentration if there 
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test. 
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
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Figure A2. Dose-response curve for DX-52-1’s effect in 4T1 cells wound closure. IC50 
values were determined by nonlinear regression analysis with GraphPad Prism software. It 
was calculated for inhibition of wound closure at 12 h post-wounding with normalization 
to parallel controls using at least 5 different subtoxic concentrations in concentration-
response experiments. The calculated IC50 value for inhibition of wound closure at 12 h by 
DX-52-1 is 30.7 µM.  
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Figure A3. Dose-response curve for DX-52-1’s anti-proliferatory effect in 4T1 cells. 
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A4. Dose-response curve for DX-52-1’s effect in 4T1 cells proliferation. IC50 
values were determined by nonlinear regression analysis with GraphPad Prism software. It 
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to 
parallel controls using at least 5 different subtoxic concentrations in concentration-
response experiments. The calculated IC50 value for inhibition of proliferation by DX-52-1 
is 695 nM.  
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Figure A5. Dose-response curve for HUK-921’s anti-proliferatory effect in 4T1 cells. 
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A6. Dose-response curve for HUK-921’s effect in 4T1 cells proliferation. IC50 
values were determined by nonlinear regression analysis with GraphPad Prism software. It 
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to 
parallel controls using at least 5 different subtoxic concentrations in concentration-
response experiments. The calculated IC50 value for inhibition of proliferation by HUK-
921 is 35.0 µM.  
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Figure A7. Dose-response curve for DX-52-1’s anti-proliferatory effect in 4T07 cells. 
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A8. Dose-response curve for DX-52-1’s effect in 4T07 cells proliferation. IC50 
values were determined by nonlinear regression analysis with GraphPad Prism software. It 
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to 
parallel controls using at least 5 different subtoxic concentrations in concentration-
response experiments. The calculated IC50 value for inhibition of proliferation by DX-52-1 
is 2.24 µM.  
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Figure A9. Dose-response curve for HUK-921’s anti-proliferatory effect in 4T07 cells. 
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A10. Dose-response curve for HUK-921’s effect in 4T07 cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by HUK-921 is 12.2 µM.  
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Figure A11. Dose-response curve for DX-52-1’s anti-proliferatory effect in B16-BL6 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A12. Dose-response curve for DX-52-1’s effect in B16-BL6 cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by DX-52-1 is 1.43 µM.  
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Figure A13. Dose-response curve for HUK-921’s anti-proliferatory effect in B16-BL6 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
 
 
 
 
Proliferation Assay- HUK on B16-BL6
co
ntr
ol-
0h
co
ntr
ol-
48
h
50
0 n
M
µΜ5 µ
Μ
25
 
µΜ
50
 
µΜ
10
0 
0
1
2
3
4

Concentrations
N
o
.
 
o
f c
el
ls
 
(40
k/
 
m
L)
85 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A14. Dose-response curve for HUK-921’s effect in B16-BL6 cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by HUK-921 is 2.48 µM.  
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Figure A15. Time course of wound closure in B16-F10 cell monolayers of HUK-921. 
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO 
or various concentrations of HUK-921. Each concentration involved at least three separate 
experiments each with multiple replicates (n, number of separately treated wounds with 
one wound per well on multiwell plates). Percent closure values are means ± standard error 
of the mean (SEM). Each concentration was considered a bioactive concentration if there 
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test. 
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
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Figure A16. Dose-response curve for HUK-921’s effect in B16-F10 cells wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
Prism software. It was calculated for inhibition of wound closure at 24 h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24h by HUK-921 is 19.6 µM.  
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Figure A17. Dose-response curve for HUK-921’s anti-proliferatory effect in B16-F10 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A18. Dose-response curve for HUK-921’s effect in B16-F10 cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by HUK-921 is 26.3 µM.  
 
 
 
 
 
 
 
HUK
-7.5 -7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5
0
40
80
120
160
200
240
280
320
360
400
440
Sigmoidal dose-response (variable slope)
Best-fit values
Bottom
Top
LogEC50
HillSlope
EC50
Std. Error
Bottom
Top
LogEC50
HillSlope
95% Confidence Intervals
Bottom
Top
LogEC50
HillSlope
EC50
Goodness of Fit
Degrees of Freedom
R square
Absolute Sum of Squares
Sy.x
Number of points
Analyzed
13.00
441.7
-4.578
-15.21
2.645e-005
4.661
2.691
2.173
270.0
3.865 to 22.13
436.4 to 446.9
-8.836 to -0.3195
-544.4 to 514.0
1.460e-009 to 0.4792
140
0.9877
72977
22.83
144
IC50 of B16-F10 for proliferation
IC50 = 26.3 µM
Log [HUK]
# 
o
f c
el
ls
 
by
 
48
h
90 
 
 
 
 
 
 
 
 
 
 
Figure A19. Dose-response curve for DX-52-1’s anti-proliferatory effect in B16-F10 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A20. Dose-response curve for DX-52-1’s effect in B16-F10 cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by DX-52-1 is 1.51 µM.  
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Figure A21. Time course of wound closure in BT20 cell monolayers of DX-52-1. 
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO 
or various concentrations of DX-52-1. Each concentration involved at least three separate 
experiments each with multiple replicates (n, number of separately treated wounds with 
one wound per well on multiwell plates). Percent closure values are means ± standard error 
of the mean (SEM). Each concentration was considered a bioactive concentration if there 
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test. 
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
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Figure A22. Dose-response curve for DX-52-1’s effect in BT20 cells wound closure. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of wound closure at 24 h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by DX-52-1 is 687 nM.  
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Figure A23. Time course of wound closure in BT20 cell monolayers of HUK-921. 
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO 
or various concentrations of HUK-921. Each concentration involved at least three separate 
experiments each with multiple replicates (n, number of separately treated wounds with 
one wound per well on multiwell plates). Percent closure values are means ± standard error 
of the mean (SEM). Each concentration was considered a bioactive concentration if there 
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test. 
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
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Figure A24. Dose-response curve for HUK-921’s effect in BT20 cells wound closure. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of wound closure at 24 h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24h by HUK-921 is not shown.  
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Figure A25. Dose-response curve for DX-52-1’s anti-proliferatory effect in BT20 cells. 
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A26. Dose-response curve for DX-52-1’s effect in BT20 cells proliferation. IC50 
values were determined by nonlinear regression analysis with GraphPad Prism software. It 
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to 
parallel controls using at least 5 different subtoxic concentrations in concentration-
response experiments. The calculated IC50 value for inhibition of proliferation by DX-52-1 
is 1.38 µM.  
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Figure A27. Dose-response curve for HUK-921’s anti-proliferatory effect in BT20 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A28. Dose-response curve for HUK-921’s effect in BT20 cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by HUK-921 is 7.08 µM.  
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Figure A29. Dose-response curve for HUK-921’s anti-proliferatory effect in Du145 
siluc cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). 
Medium changed after growing the cells for 24 hrs in the presence or absence of HUK-
921. After another 48hrs, cell numbers were counted with the Cell Counting Kit-8 
(Dojindo), a tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax 
Plus384, Molecular devices) based on manufacturer's protocol. Cell numbers are means ± 
standard error of the mean (SEM). Each concentration was considered a bioactive 
concentration if there was statistically significant inhibition with P < 0.05 by unpaired two-
tailed Student’s t-test. 
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Figure A30. Dose-response curve for HUK-921’s effect in Du145 siluc cells 
proliferation. IC50 values were determined by nonlinear regression analysis with 
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h post-
treatment with normalization to parallel controls using at least 5 different subtoxic 
concentrations in concentration-response experiments. The calculated IC50 value for 
inhibition of proliferation by HUK-921 is 11.7 µM.  
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Figure A31. Dose-response curve for DX-52-1’s anti-proliferatory effect in Du145 
siluc cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). 
Medium changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. 
After another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A32. Dose-response curve for DX-52-1’s effect in Du145 siluc cells 
proliferation. IC50 values were determined by nonlinear regression analysis with 
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h post-
treatment with normalization to parallel controls using at least 5 different subtoxic 
concentrations in concentration-response experiments. The calculated IC50 value for 
inhibition of proliferation by DX-52-1 is 314 nM.  
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Figure A33. Time course of wound closure in 168FARN cell monolayers of HUK-921. 
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO 
or various concentrations of HUK-921. Each concentration involved at least three separate 
experiments each with multiple replicates (n, number of separately treated wounds with 
one wound per well on multiwell plates). Percent closure values are means ± standard error 
of the mean (SEM). Each concentration was considered a bioactive concentration if there 
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test. 
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
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Figure A34. Dose-response curve for HUK-921’s effect in 168FARN cells wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
Prism software. It was calculated for inhibition of wound closure at 48h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 48h by HUK-921 is 43.5 µM. 
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Figure A35. Dose-response curve for DX-52-1’s anti-proliferatory effect on 168FARN 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A36. Dose-response curve for DX-52-1’s effect in 168FARN cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by DX-52-1 is 1.96 µM.  
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Figure A37. Dose-response curve for HUK-921’s anti-proliferatory effect in 
168FARN cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per 
mL). Medium changed after growing the cells for 24 hrs in the presence or absence of 
HUK-921. After another 48hrs, cell numbers were counted with the Cell Counting Kit-8 
(Dojindo), a tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax 
Plus384, Molecular devices) based on manufacturer's protocol. Cell numbers are means ± 
standard error of the mean (SEM). Each concentration was considered a bioactive 
concentration if there was statistically significant inhibition with P < 0.05 by unpaired two-
tailed Student’s t-test. 
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Figure A38. Dose-response curve for HUK-921’s effect in 168FARN cells 
proliferation. IC50 values were determined by nonlinear regression analysis with 
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h post-
treatment with normalization to parallel controls using at least 5 different subtoxic 
concentrations in concentration-response experiments. The calculated IC50 value for 
inhibition of proliferation by HUK-921 is 32.9 µM.  
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Figure A39. Dose-response curve for HUK-921’s anti-proliferatory effect in MCF7 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A40. Dose-response curve for HUK-921’s effect in MCF7 cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by HUK-921 is 10.8 µM.  
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Figure A41. Dose-response curve for DX-52-1’s anti-proliferatory effect on MCF7 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A42. Dose-response curve for DX-52-1’s effect in MCF7 cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by DX-52-1 is 176 nM.  
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Figure A43. Time course of wound closure in MDA-MB-231 cell monolayers of DX-
52-1. Percent wound closure is depicted as a function of time after treatment with: 0.05% 
DMSO or various concentrations of DX-52-1. Each concentration involved at least three 
separate experiments each with multiple replicates (n, number of separately treated wounds 
with one wound per well on multiwell plates). Percent closure values are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
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Figure A44. Dose-response curve for DX-52-1’s effect in MDA-MB-231 cells wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
Prism software. It was calculated for inhibition of wound closure at 24 h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by DX-52-1 is 57.4 µM. 
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Figure A45. Dose-response curve for DX
MB-231 cells. Cells were plated into 96
Medium changed after growing the cells for 24 hrs in the presence 
After another 48hrs, cell numbers were
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus
Molecular devices) based on manufacturer's protocol.
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with 
t-test. 
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Figure A46. Dose-response curve for HUK
MB-231 cells. Cells were plated into 96
Medium changed after growing the cells for 24 hrs in the presence 
921. After another 48hrs, cell numbers were
(Dojindo), a tetrazolium salt
Plus384, Molecular devices) based on manufacturer's protocol.
standard error of the mean (SEM). Each concentration was considered a bioactive 
concentration if there was statistically significant inhibition with 
tailed Student’s t-test. 
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Figure A47. Dose-response curve for HUK-921’s effect in MDA-MB-231 cells 
proliferation. IC50 values were determined by nonlinear regression analysis with 
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h post-
treatment with normalization to parallel controls using at least 5 different subtoxic 
concentrations in concentration-response experiments. The calculated IC50 value for 
inhibition of proliferation by HUK-921 is 27.3 µM.  
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Figure A48. Time course of wound closure in MDA-MB-435 cell monolayers of DX-
52-1. Percent wound closure is depicted as a function of time after treatment with: 0.05% 
DMSO or various concentrations of DX-52-1. Each concentration involved at least three 
separate experiments each with multiple replicates (n, number of separately treated wounds 
with one wound per well on multiwell plates). Percent closure values are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
 
 
 
 
10 20 30 40
-20
-10
0
10
20
30
40
50
60
70
80
90
100
DX-52-1 has effect on MDA/ MB 435
0.01% DMSO on MDA 435 ( n=12)
50 nM DX on MDA 435 ( n=12 )
200 nM DX on MDA 435 ( n=12 )
500 nM DX on MDA 435 ( n=12 )
100 nM DX on MDA 435 ( n=12 )
Time (h)
Pe
rc
en
t w
ou
n
d 
clo
su
re
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A49. Dose-response curve for DX-52-1’s effect in MDA-MB-435 cells wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
Prism software. It was calculated for inhibition of wound closure at 24 h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by DX-52-1 is 213 nM. 
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Figure A50. Time course of wound closure in MDA-MB-435 cell monolayers of HUK-
921. Percent wound closure is depicted as a function of time after treatment with: 0.05% 
DMSO or various concentrations of HUK-921. Each concentration involved at least three 
separate experiments each with multiple replicates (n, number of separately treated wounds 
with one wound per well on multiwell plates). Percent closure values are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
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Figure A51. Dose-response curve for HUK-921’s effect in MDA-MB-435 cells wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
Prism software. It was calculated for inhibition of wound closure at 24h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24h by HUK-921 is 24.4 µM. 
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Figure A52. Dose-response curve for DX-52-1’s effect in MDA-MB-435 cells 
proliferation. IC50 values were determined by nonlinear regression analysis with 
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h post-
treatment with normalization to parallel controls using at least 5 different subtoxic 
concentrations in concentration-response experiments. The calculated IC50 value for 
inhibition of proliferation by DX-52-1 is 163 nM.  
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Figure A53. Time course of wound closure in T47D cell monolayers of HUK-921. 
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO 
or various concentrations of HUK-921. Each concentration involved at least three separate 
experiments each with multiple replicates (n, number of separately treated wounds with 
one wound per well on multiwell plates). Percent closure values are means ± standard error 
of the mean (SEM). Each concentration was considered a bioactive concentration if there 
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test. 
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
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Figure A54. Dose-response curve for HUK-921’s effect in T47D cells wound closure. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of wound closure at 36h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 36h by HUK-921 is 44.5 µM. 
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Figure A55. Dose-response curve for HUK-921’s anti-proliferatory effect in T47D 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A56. Dose-response curve for HUK-921’s effect in T47D cells proliferation. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of proliferation at 48 h post-treatment with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of 
proliferation by HUK-921 is 12.1 µM.  
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Figure A57. Time course of wound closure in T47D cell monolayers of DX-52-1. 
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO 
or various concentrations of DX-52-1. Each concentration involved at least three separate 
experiments each with multiple replicates (n, number of separately treated wounds with 
one wound per well on multiwell plates). Percent closure values are means ± standard error 
of the mean (SEM). Each concentration was considered a bioactive concentration if there 
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test. 
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye 
exclusion assay, as well as observation of any rounding up of cells in this and subsequent 
figures. 
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Figure A58. Dose-response curve for DX-52-1’s effect in T47D cells wound closure. 
IC50 values were determined by nonlinear regression analysis with GraphPad Prism 
software. It was calculated for inhibition of wound closure at 36 h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 36 h by DX-52-1 is 53.7 nM. 
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Figure A59. Dose-response curve for DX-52-1’s anti-proliferatory effect on T47D 
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium 
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After 
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a 
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384, 
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard 
error of the mean (SEM). Each concentration was considered a bioactive concentration if 
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s 
t-test. 
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Figure A60. Dose-response curve for DX-52-1’s effect in T47D cells proliferation. IC50 
values were determined by nonlinear regression analysis with GraphPad Prism software. It 
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to 
parallel controls using at least 5 different subtoxic concentrations in concentration-
response experiments. The calculated IC50 value for inhibition of proliferation by DX-52-1 
is 228 nM. 
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